FDA Denies Somaxon Pharmaceuticals, Inc. Approval for Insomnia Drug

February 27, 2009 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Feb 26 (Reuters) - Somaxon Pharmaceuticals Inc said the U.S. health regulators denied approval for its experimental treatment for insomnia in the present form and raised several issues regarding the efficacy data of the drug.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory

Food and Drug Administration (FDA)